Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade
Nat Med
.
2021 Mar;27(3):560.
doi: 10.1038/s41591-021-01246-4.
Authors
Kobe C Yuen
#
1
,
Li-Fen Liu
#
1
,
Vinita Gupta
1
,
Shravan Madireddi
1
,
Shilpa Keerthivasan
1
,
Congfen Li
1
,
Deepali Rishipathak
1
,
Patrick Williams
1
,
Edward E Kadel 3rd
1
,
Hartmut Koeppen
1
,
Ying-Jiun Chen
1
,
Zora Modrusan
1
,
Jane L Grogan
1
,
Romain Banchereau
1
,
Ning Leng
1
,
AnnChristine Thastrom
1
,
Xiadong Shen
1
,
Kenji Hashimoto
2
,
Darren Tayama
1
,
Michiel S van der Heijden
3
,
Jonathan E Rosenberg
4
,
David F McDermott
5
,
Thomas Powles
6
,
Priti S Hegde
1
,
Mahrukh A Huseni
7
,
Sanjeev Mariathasan
8
Affiliations
1
Genentech, San Francisco, CA, USA.
2
Roche Products Ltd., Welwyn Garden City, UK.
3
Netherlands Cancer Institute, Amsterdam, the Netherlands.
4
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
5
Beth Israel Deaconess Medical Center, Boston, MA, USA.
6
Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK.
7
Genentech, San Francisco, CA, USA.
[email protected]
.
8
Genentech, San Francisco, CA, USA.
[email protected]
.
#
Contributed equally.
PMID:
33547461
DOI:
10.1038/s41591-021-01246-4
No abstract available
Publication types
Published Erratum